ArticleJournal of surgical oncology2015
The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.
Article in Journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Lymphatic Complications in Patients Undergoing Melanoma Surgery in Peru.Plastic and reconstructive surgery. Global open · 2026Article
- Lymphoedema Development Following a Cancer Diagnosis: An Anonymised Data Linkage Study in Wales, United Kingdom.International wound journal · 2025Observational
- The MD Anderson Algorithm for Lymphedema Management.Journal of clinical medicine · 2025Review
- Demystifying vascularized lymph node transfers and lymphatico-venous anastomoses.Annals of translational medicine · 2024Review
- Role of inducible nitric oxide (iNOS) and nitrosative stress in regulating sex differences in secondary lymphedema.Frontiers in physiology · 2024Article
- Lymphoedema surgery in Australia: a narrative review.Gland surgery · 2023Review
- Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.BMC cancer · 2023Article
- Mitigating Breast-Cancer-Related Lymphedema-A Calgary Program for Immediate Lymphatic Reconstruction (ILR).Current oncology (Toronto, Ont.) · 2023Review
- Treatment of end-stage lymphedema following radiotherapy for lymphoma: A case report.Medicine · 2021Article
- Combined deep inferior epigastric artery perforator flap with vascularized groin lymph node transplant for treatment of breast cancer-related lymphedema.Gland surgery · 2021Review
- Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer.Physical therapy · 2020Observational
- Building a Multidisciplinary Comprehensive Academic Lymphedema Program.Plastic and reconstructive surgery. Global open · 2020Article
- Lymphovenous Anastomosis Bypass Surgery.Seminars in plastic surgery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesWe assessed the cumulative incidence, symptoms, and risk factors for upper-extremity lymphedema in breast cancer and melanoma patients undergoing sentinel lymph node biopsy or axillary lymph node dissection.
methodsPatients were recruited preoperatively (time 0) and assessed at 6, 12, and 18 months postoperatively. Limb volume change (LVC) was measured by perometry. Lymphedema was categorized as none, mild (LVC 5-9.9%), or moderate/severe (LVC≥10%). Symptoms were assessed with a validated lymphedema instrument. Longitudinal logistic regression analyses were conducted to identify risk factors associated with moderate/severe lymphedema.
resultsAmong 205 breast cancer and 144 melanoma patients, the cumulative incidence of moderate/severe lymphedema at 18 months was 36.5% and 35.0%, respectively. However, in adjusted analyses, factors associated with moderate/severe lymphedema were breast cancer (OR 2.0, P = 0.03), body mass index ≥ 30 kg/m(2) (OR 1.6, P = 0.04), greater number of lymph nodes removed (OR 1.05, P < 0.01), and longer interval since surgery (OR 2.33 at 18 months, P < 0.01).
conclusionsLymphedema incidence increased over time in both cohorts. However, the adjusted risk of moderate/severe lymphedema was two-fold higher in breast cancer patients. These results may be attributed to surgical treatment of the primary tumor in the breast and more frequent use of radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.